NCT03259035 2026-04-09
NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer
Canadian Cancer Trials Group
Phase 2 Completed
Clinical Trials
120 trialsNCT02359968 2026-03-18
PROTECT
Centre Oscar Lambret
Phase 2 Completed
NCT05702229 2026-03-18
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
AstraZeneca
Phase 2 Recruiting
NCT07323576 2026-02-09
INAVO-CRC
Hoffmann-La Roche
Phase 2 Withdrawn
NCT03092895 2026-01-29
A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT07353827 2026-01-20
FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06106308 2026-01-12
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Cardiff Oncology
Phase 2 Active not recruiting
NCT06154538 2025-11-28
Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06846346 2025-11-28
GRACIE
UNICANCER
Phase 2 Recruiting
NCT06529718 2025-11-17
SEVILLA
UNICANCER
Phase 2 Recruiting
NCT04656041 2025-11-14
Folfox+Irinotecan+Chemort In Esophageal Cancer
Massachusetts General Hospital
Phase 2 Recruiting
NCT04595266 2025-09-29
LIVERPEARL
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 2 Active not recruiting
NCT07192185 2025-09-25
Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
Sun Yat-sen University
Phase 2 Recruiting
NCT06253611 2025-09-22
BIG
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Recruiting
NCT05024097 2025-08-27
PANTHER
Weill Medical College of Cornell University
Phase 2 Recruiting
NCT07106034 2025-08-12
ONTOP
Shanghai Pudong Hospital
Phase 2 Not yet recruiting
NCT05480306 2025-08-03
DeFianCe
Leap Therapeutics, Inc.
Phase 2 Completed
NCT03186326 2025-06-29
SAMCO
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT03584711 2025-06-29
OPTIPRIME
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT05712356 2025-06-06
BOLSTER
Lisata Therapeutics, Inc.
Phase 2 Active not recruiting
NCT06991465 2025-05-28
Hypo-OPRA
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase 2 Recruiting
NCT05312398 2025-05-25
CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen
University of Campania Luigi Vanvitelli
Phase 2 Active not recruiting
NCT06907342 2025-05-25
COSENSE-1
St. Olavs Hospital
Phase 2 Recruiting
NCT06972498 2025-05-15
A Prospective Multicenter Study: Ivosimab + Chemotherapy as Neoadjuvant for Resectable pMMR/MSS CRC Liver Mets
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 2 Not yet recruiting
NCT06946849 2025-04-27
SED-RO-ICC
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT03861702 2025-04-18
Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT06919848 2025-04-09
Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)
Fudan University
Phase 2 Not yet recruiting
NCT03548961 2025-04-04
Organ Preservation in Early Rectal Cancer Patients
Fox Chase Cancer Center
Phase 2 Active not recruiting
NCT05864105 2025-03-12
PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma
Biotheus Inc.
Phase 2 Active not recruiting
NCT04380337 2025-02-25
Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer
Stanford University
Phase 2 Completed
NCT06225843 2025-02-19
EGIA-003
Alethia Biotherapeutics
Phase 2 Recruiting
NCT03117972 2025-02-05
CLavSyn
Centre Hospitalier Universitaire de Besancon
Phase 2 Terminated
NCT03662659 2025-02-05
An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
Bristol-Myers Squibb
Phase 2 Completed
NCT02000050 2025-01-30
COLORE
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Completed
NCT06475352 2025-01-27
FUDOSE
UNICANCER
Phase 2 Recruiting
NCT03781323 2024-12-13
Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer
University of Rochester
Phase 2 Active not recruiting
NCT05476796 2024-10-24
LOGICAN
UNICANCER
Phase 2 Recruiting
NCT05039944 2024-07-18
SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Terminated
NCT01274962 2024-06-26
A Study on the Timing of FOLFOX for Patients With Operable, Node Positive Rectal Cancer
Sir Mortimer B. Davis - Jewish General Hospital
Phase 2 Completed
NCT06218810 2024-01-23
Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer
Fudan University
Phase 2 Recruiting
NCT06123455 2023-11-08
Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric Cancer
Tang-Du Hospital
Phase 2 Unknown
NCT02243358 2023-10-27
Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer
Henry Ford Health System
Phase 2 Completed
NCT02017704 2023-10-17
CORRECT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01622543 2023-08-23
Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT06003998 2023-08-22
INTERACT-II
Catharina Ziekenhuis Eindhoven
Phase 2 Unknown
NCT05099848 2023-08-15
A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute
Phase 2 Unknown
NCT04217954 2023-06-23
HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC
Peking University
Phase 2 Completed
NCT04962958 2023-06-22
Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT05886465 2023-06-02
HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial
Sun Yat-sen University
Phase 2 Unknown
NCT05797883 2023-04-04
FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer
China Medical University, China
Phase 2 Unknown